Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Feb;82(3):905–909. doi: 10.1073/pnas.82.3.905

Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation.

C L Koski, R Humphrey, M L Shin
PMCID: PMC397156  PMID: 3856240

Abstract

The role of anti-peripheral nerve myelin antibody (anti-PNM Ab) in the pathogenesis of acquired demyelination of peripheral nerve is unclear, in part, due to the poor correlation between antibody and disease activity. Previous studies show that only 27-50% of patients with acute demyelinating neuropathy or Guillain-Barré syndrome (GBS) had serum Abs to peripheral nerve or PNM as demonstrated by consumption of hemolytic activity of serum complement 1 (C1) fixation and transfer assay, quantitative determinations of anti-PNM Ab showed significantly high titers in the serum of patients with GBS, chronic and recurrent polyneuritis, and paraproteinemia associated with peripheral neuropathy. All 11 patients with acute-phase GBS had Ab titers 6-56 times higher than controls. In 6 GBS patients, serial Ab determinations showed that titers were highest on admission, fell rapidly the first week, and became undetectable or barely detectable by the third week. Declining Ab titers coincided with cessation of clinical progression. In 3 GBS patients, depletion of serum IgM lowered anti-PNM Ab titers significantly, whereas IgG depletion failed to produce a similar effect. This study shows that the C1 fixation and transfer assay is a sensitive method to detect anti-PNM Ab in the serum of patients with a variety of demyelinating neuropathies and provides good correlation between Ab level and the clinical course of GBS patients. It may provide important information about the pathogenesis of the demyelinating neuropathies.

Full text

PDF
905

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borsos T., Rapp H. J. Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol. 1965 Sep;95(3):559–566. [PubMed] [Google Scholar]
  2. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978 Jun;3(6):565–566. doi: 10.1002/ana.410030628. [DOI] [PubMed] [Google Scholar]
  3. Feasby T. E., Hahn A. F., Gilbert J. J. Passive transfer studies in Guillain-Barré polyneuropathy. Neurology. 1982 Oct;32(10):1159–1167. doi: 10.1212/wnl.32.10.1151-a. [DOI] [PubMed] [Google Scholar]
  4. Hong K., Kinoshita T., Inoue K. Simple methods for preparing EAC1,4b,2a,3b and EAC4b,3b with human or guinea pig complement components using an anticomplementary agent, K-76 monocarboxylic acid. J Immunol. 1981 Jul;127(1):109–114. [PubMed] [Google Scholar]
  5. Hong K., Kinoshita T., Kitajima H., Inoue K. Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system. J Immunol. 1981 Jul;127(1):104–108. [PubMed] [Google Scholar]
  6. Hong K., Kinoshita T., Miyazaki W., Izawa T., Inoue K. An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade. J Immunol. 1979 Jun;122(6):2418–2423. [PubMed] [Google Scholar]
  7. Iida K., Fujita T., Inai S., Sasaki M., Kato T. Complement fixing abilities of IgA myeloma proteins and their fragments: the activation of complement through the classical pathway. Immunochemistry. 1976 Sep;13(9):747–752. doi: 10.1016/0019-2791(76)90195-6. [DOI] [PubMed] [Google Scholar]
  8. Ishizaka T., Ishizaka K., Borsos T., Rapp H. C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody. J Immunol. 1966 Nov;97(5):716–726. [PubMed] [Google Scholar]
  9. Latov N., Gross R. B., Kastelman J., Flanagan T., Lamme S., Alkaitis D. A., Olarte M. R., Sherman W. H., Chess L., Penn A. S. Complement-fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia. Neurology. 1981 Dec;31(12):1530–1534. doi: 10.1212/wnl.31.12.1530. [DOI] [PubMed] [Google Scholar]
  10. Latov N., Sherman W. H., Nemni R., Galassi G., Shyong J. S., Penn A. S., Chess L., Olarte M. R., Rowland L. P., Osserman E. F. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med. 1980 Sep 11;303(11):618–621. doi: 10.1056/NEJM198009113031105. [DOI] [PubMed] [Google Scholar]
  11. Liu W. T., Vanguri P., Shin M. L. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J Immunol. 1983 Aug;131(2):778–782. [PubMed] [Google Scholar]
  12. MELNICK S. C. Thirty-eight cases of the Guillain-Barre syndrome: an immunological study. Br Med J. 1963 Feb 9;1(5327):368–373. doi: 10.1136/bmj.1.5327.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  14. Markwell M. A., Haas S. M., Bieber L. L., Tolbert N. E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978 Jun 15;87(1):206–210. doi: 10.1016/0003-2697(78)90586-9. [DOI] [PubMed] [Google Scholar]
  15. Norton W. T. Isolation of myelin from nerve tissue. Methods Enzymol. 1974;31:435–444. doi: 10.1016/0076-6879(74)31049-x. [DOI] [PubMed] [Google Scholar]
  16. Rosenberg R. N., Aung M. H., Tindall R. S., Molenich S., Baskin R., Capra J. D., Toben H. R. Idiopathic polyneuropathy associated with cytotoxic anti-neuroblastoma serum. IgG and IgM immunoglobulin studies. Neurology. 1975 Dec;25(12):1101–1110. doi: 10.1212/wnl.25.12.1101. [DOI] [PubMed] [Google Scholar]
  17. Saida T., Saida K., Lisak R. P., Brown M. J., Silberberg D. H., Asbury A. K. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann Neurol. 1982 Jan;11(1):69–75. doi: 10.1002/ana.410110112. [DOI] [PubMed] [Google Scholar]
  18. Stroud R. M., Mayer M. M., Miller J. A., McKenzie A. T. C'2ad, an inactive derivative of C'2 released during decay of EAC'4,2a. Immunochemistry. 1966 May;3(3):163–176. doi: 10.1016/0019-2791(66)90182-0. [DOI] [PubMed] [Google Scholar]
  19. Tse K. S., Arbesman C. E., Tomasi T. B., Jr, Tourville D. Demonstration of antimyelin antibodies by immunofluorescence in Guillain-Barré syndrome. Clin Exp Immunol. 1971 Jun;8(6):881–887. [PMC free article] [PubMed] [Google Scholar]
  20. Vanguri P., Koski C. L., Silverman B., Shin M. L. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci U S A. 1982 May;79(10):3290–3294. doi: 10.1073/pnas.79.10.3290. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES